Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

О нас

Контакты

[email protected]

Мы в соцсетях

Instagram
Telegram
LinkedIn

Все права защищены.

Условия использования

Главная
Рынки
Скринер
Новости
О нас

EXOZ - eXoZymes, Inc. Последние новости | Finranks

Home

EXOZ

E

eXoZymes, Inc. (EXOZ)

NCM – Цена в реальном времени. Валюта: USD

7.15

-0.08 (-1.11%)

При закрытии: Mar 27, 2026, 4:00 PM EDT

7.17

+0.02 (0.28%)

После закрытия: Mar 27, 2026, 4:04 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

eXoZymes to Host Fourth Quarter and Full Year 2025 Results Conference Call on Tuesday March 31, 2026

eXoZymes to Host Fourth Quarter and Full Year 2025 Results Conference Call on Tuesday March 31, 2026

LOS ANGELES, CA / ACCESS Newswire / March 25, 2026 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that transforms abundant feedstock into valuable nutraceuticals and novel medicines - announced the plan to host a webinar on Tuesday, March 31, 2026 at 5:30 PM Eastern Time to discuss its results for the fourth quarter and full year 2025. A press release detailing these results will be issued prior to the call.

Successful Pilot Scale Run with Cayman Chemical Validates eXoZymes' Technology and Scalability

Successful Pilot Scale Run with Cayman Chemical Validates eXoZymes' Technology and Scalability

LOS ANGELES, CA / ACCESS Newswire / March 18, 2026 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that transforms abundant feedstock into valuable nutraceuticals and novel medicines - announced an important validation and de-risking milestone for its cell-free biomanufacturing platform: An independent partner, Cayman Chemical, successfully ran eXoZymes' technology at pilot scale and achieved results consistent with - and in some cases exceeding - earlier internal runs. Using eXoZymes' tech transfer package, Cayman Chemical advanced the protocol from a one-liter setup to a 100-liter pilot run, operating the reaction, downstream processing, and analysis independently.

eXoZymes' CCO Damien Perriman to Present a NCT Solution at Next Week's MISTA Symposium

eXoZymes' CCO Damien Perriman to Present a NCT Solution at Next Week's MISTA Symposium

LOS ANGELES, CA / ACCESS Newswire / March 12, 2026 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that transforms abundant feedstock into valuable nutraceuticals and novel medicines - announced that Perriman will present a solution for scaling production of NCT, a naturally occurring small molecule currently being developed by eXoZymes for both nutraceutical and pharmaceutical applications. The presentation will focus on NCT's potential role in metabolic health and its emerging relevance in the rapidly evolving landscape of food, supplements, and longevity-focused wellness solutions.

With Refreshed Brand eXoZymes Sharpens Pharmaceutical Focus to Drive Platform Leverage and Long-Term Value Creation

LOS ANGELES, CALIFORNIA / ACCESS Newswire / February 10, 2026 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes transforming abundant feedstock into valuable nutraceuticals and new medicines - announced the launch of a redesigned corporate website and updated visual identity, reflecting the company's refined strategic focus on pharmaceutical and nutraceutical markets. The update follows the company's previously communicated decision to sharpen its commercial scope toward sectors where management believes its AI-enhanced, cell-free exozyme platform may provide differentiated capabilities and long-term value creation potential.

eXoZymes Advancing Commercial Readiness With Profound Production Metrics on Initial NCT Pilot Run

eXoZymes Advancing Commercial Readiness With Profound Production Metrics on Initial NCT Pilot Run

N-trans-caffeoyltyramine (NCT) is an interesting naturally occurring compound that has attracted scientific attention in exploratory studies related to lipid metabolism and energy utilization pathways. The production was executed by an external partner under pilot-scale conditions using standardized protocols.

eXoZymes Achieves 100× Scale-up of NCT Production Using Exozymes, Demonstrating Near-perfect Feedstock Conversion

eXoZymes Achieves 100× Scale-up of NCT Production Using Exozymes, Demonstrating Near-perfect Feedstock Conversion

LOS ANGELES, CALIFORNIA / ACCESS Newswire / December 11, 2025 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that can transform sustainable feedstock into nutraceuticals and new medicines - announced the successful achievement of a 100-fold scale-up of its N-trans-caffeoyltyramine (NCT) production process using its proprietary exozyme-based, cell-free biomanufacturing platform. This effort, with a conversion level of over 99% from feedstock to product, marks a major milestone in the scalability of the exozymes platform.

eXoZymes Provides Third Quarter 2025 Update at 5PM EST Today

eXoZymes Provides Third Quarter 2025 Update at 5PM EST Today

Management to host Q3 2025 update at 5:00PM Eastern Time, today. LOS ANGELES, CALIFORNIA / ACCESS Newswire / November 13, 2025 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that can transform sustainable feedstock into nutraceuticals and new medicines - plans to host a webinar at 5:00 PM Eastern Time to provides an update on operations through the fiscal quarter that ended October 31, 2025.

Видео

No Data

There is no data to display

Пресс-релизы

Successful Pilot Scale Run with Cayman Chemical Validates eXoZymes' Technology and Scalability

Successful Pilot Scale Run with Cayman Chemical Validates eXoZymes' Technology and Scalability

LOS ANGELES, CA / ACCESS Newswire / March 18, 2026 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that transforms abundant feedstock into valuable nutraceuticals and novel medicines - announced an important validation and de-risking milestone for its cell-free biomanufacturing platform: An independent partner, Cayman Chemical, successfully ran eXoZymes' technology at pilot scale and achieved results consistent with - and in some cases exceeding - earlier internal runs. Using eXoZymes' tech transfer package, Cayman Chemical advanced the protocol from a one-liter setup to a 100-liter pilot run, operating the reaction, downstream processing, and analysis independently.

With Refreshed Brand eXoZymes Sharpens Pharmaceutical Focus to Drive Platform Leverage and Long-Term Value Creation

LOS ANGELES, CALIFORNIA / ACCESS Newswire / February 10, 2026 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes transforming abundant feedstock into valuable nutraceuticals and new medicines - announced the launch of a redesigned corporate website and updated visual identity, reflecting the company's refined strategic focus on pharmaceutical and nutraceutical markets. The update follows the company's previously communicated decision to sharpen its commercial scope toward sectors where management believes its AI-enhanced, cell-free exozyme platform may provide differentiated capabilities and long-term value creation potential.

eXoZymes Advancing Commercial Readiness With Profound Production Metrics on Initial NCT Pilot Run

eXoZymes Advancing Commercial Readiness With Profound Production Metrics on Initial NCT Pilot Run

N-trans-caffeoyltyramine (NCT) is an interesting naturally occurring compound that has attracted scientific attention in exploratory studies related to lipid metabolism and energy utilization pathways. The production was executed by an external partner under pilot-scale conditions using standardized protocols.

eXoZymes Achieves 100× Scale-up of NCT Production Using Exozymes, Demonstrating Near-perfect Feedstock Conversion

eXoZymes Achieves 100× Scale-up of NCT Production Using Exozymes, Demonstrating Near-perfect Feedstock Conversion

LOS ANGELES, CALIFORNIA / ACCESS Newswire / December 11, 2025 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that can transform sustainable feedstock into nutraceuticals and new medicines - announced the successful achievement of a 100-fold scale-up of its N-trans-caffeoyltyramine (NCT) production process using its proprietary exozyme-based, cell-free biomanufacturing platform. This effort, with a conversion level of over 99% from feedstock to product, marks a major milestone in the scalability of the exozymes platform.